Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines

Anna-Karin M Sjogren1, Maria Liljevald, Björn Glinghammar

  • 1Cardiovascular and Metabolic Diseases Innovative Medicines, DMPK, AstraZeneca R&D, 431 83, Mölndal, Sweden, anna-karin.sjogren@astrazeneca.com.